Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis
The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
In this study, we employed a sensitive activity assay system to measure cerebrospinal fluid (CSF) and serum levels of active matrix metalloproteinase-9 (MMP-9) in 37 relapsing-remitting (RR), 15 secondary progressive (SP) and nine primary progressive (PP) multiple sclerosis (MS) patients, grouped according to clinical and magnetic resonance imaging (MRI) evidence of disease activity. We also studied, as neurological controls, 48 patients with other inflammatory neurological disorders (OIND) and 48 with non-inflammatory neurological disorders (NIND). To assess active MMP-9/TIMP-1 circuit, CSF and serum levels of MMP-9 tissue inhibitor TIMP-1 were quantified by ELISA in the same patient population. CSF mean levels of active MMP-9, CSF active MMP-9/TIMP-1 ratios and intrathecal active MMP-9 synthesis, as indicated by specific index, were more elevated in MS than in NIND ( P <0.05, <0.02 and <0.02, respectively), serum active MMP-9/TIMP-1 ratio was higher in MS ( P<0.01) and OIND ( P<0.02) than in NIND, and serum TIMP-1 concentrations were lower in MS than in NIND ( P<0.05). More importantly, serum active MMP-9 mean levels, serum active MMP-9/TIMP-1 ratio and intrathecal production of active MMP-9 were increased in MS patients with clinical ( P<0.001, <0.001 and <0.05, respectively) and MRI ( P<0.001, <0.001 and <0.02, respectively) disease activity, whereas CSF mean concentrations of active MMP-9 and CSF active MMP-9/TIMP-1 ratio were enhanced only in MS patients with MRI evidence of disease activity ( P<0.02 and <0.01, respectively). Altogether, these findings suggest that a shift in MMP-9/TIMP-1 balance towards proteolytic activity of MMP-9 could be relevant in MS immune dysregulation. In addition, our results indicate that CSF and serum levels of active MMP-9 may represent a potential surrogate biomarker for monitoring MS disease activity. In particular, serum active MMP-9/TIMP-1 ratio seems to be a very appropriate indicator of ongoing MS inflammation, since it is easily measurable.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Elevated Qalb values (355), increased MMP-9 activity in CSF and serum (122, 168), and increased CSF leukocyte count (122), all indicative of BBB breakdown, have been shown in MS patients at different stages of the disease.”
From Blood-Brain Barrier: From Physiology to Disease and Back (2019) · cites this paper as [168]
In the citing paper
“As in a venous ulcer, a key determinant of tissue injury is played by MMP9. Exactly as in CVD, the over-expression of MMP9 is insufficiently counterbalanced by its tissue inhibitor TIMP-1.”
From The Big Idea: Iron-Dependent Inflammation in Venous Disease and Proposed Parallels in Multiple Sclerosis (2006) · cites this paper as [30]
In the citing paper
“MMP9 can trigger leukocyte transen-dothelial traffic through an altered BBB, and serum active MMP9/TIMP-1 is now considered an appropriate indicator of ongoing MS inflammation.30”
From The Big Idea: Iron-Dependent Inflammation in Venous Disease and Proposed Parallels in Multiple Sclerosis (2006) · cites this paper as [30]
Citations
Cites
Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)
Kurtzke, J. F. (1983) · Neurology · doi:10.1212/wnl.33.11.1444 · Cited by 15,011
New diagnostic criteria for multiple sclerosis: Guidelines for research protocols
Poser, C. M., Paty, D. W., Scheinberg, L., McDonald, W. I., Davis, F. A., Ebers, G. C., Johnson, K. P., Sibley, W. A., Silberberg, D. H., & Tourtellotte, W. W. (1983) · Annals of Neurology · doi:10.1002/ana.410130302 · Cited by 7,384
McDonald, W. I., Compston, A., Edan, G., Goodkin, D., Hartung, H., Lublin, F. D., McFarland, H. F., Paty, D. W., Polman, C. H., Reingold, S. C., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1032 · Cited by 6,969
Defining the clinical course of multiple sclerosis: Results of an international survey
Lublin, F. D., Reingold, S. C., & National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis* (1996) · Neurology · doi:10.1212/wnl.46.4.907 · Cited by 3,686
Compston, A., & Coles, A. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08220-x · Cited by 1,743
Metalloproteinases in biology and pathology of the nervous system
Yong, V. W., Power, C., Forsyth, P., & Edwards, D. R. (2001) · Nature Reviews Neuroscience · doi:10.1038/35081571 · Cited by 1,060
Tibbling, G., Link, H., & Ohman, S. (1977) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.1080/00365517709091496 · Cited by 966
Tibbling, G., Link, H., & Ohman, S. (1977) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.3109/00365517709091496 · Cited by 813
Bar-Or, A. (2003) · Brain · doi:10.1093/brain/awg285 · Cited by 360
Development of biomarkers in multiple sclerosis
Bielekova, B., & Martin, R. (2004) · Brain · doi:10.1093/brain/awh176 · Cited by 299
Cited by
Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders
Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.188 · Cited by 3,076
Blood-Brain Barrier: From Physiology to Disease and Back
Sweeney, M. D., Zhao, Z., Montagne, A., Nelson, A. R., & Zlokovic, B. V. (2019) · Physiological Reviews · doi:10.1152/physrev.00050.2017 · Cited by 2,312
Tesmer, L. A., Lundy, S. K., Sarkar, S., & Fox, D. A. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00628.x · Cited by 1,102
Farace, C., Melguizo, C., Asara, Y., Álvarez, P., Prados, J. C., Tolu, P., Delogu, G., Aránega, A., & Madeddu, R. (2011) · Cited by 464
Astrocytes—Friends or foes in multiple sclerosis?
Williams, A., Piaton, G., & Lubetzki, C. (2007) · Glia · doi:10.1002/glia.20546 · Cited by 302
“…in active lesions (Cossins et al., 1997; Diaz-Sanchez et al., 2006; Maeda and Sobel, 1996; van Horssen et al., 2006), and MMP expression in serum and cerebrospinal fluid (CSF) is also increased, especially in active disease (Avolio et al., 2003; Fainardi et al., 2006; Kanesaka et al., 2006).”
Background
Metadata
- Authors
- Fainardi, E., Castellazzi, M., Bellini, T., Manfrinato, M. C., Baldi, E., Casetta, I., Paolino, E., Granieri, E., & Dallocchio, F.
- Affiliations
- University of Ferrara (IT)
- Corresponding author
- Fainardi, E
- Venue
- Multiple Sclerosis Journal
- Publisher
- SAGE Publications
- Published
- 2006-06
- Volume
- 12
- Issue
- 3
- Pages
- 294-301
- ISSN
- 1352-4585 (ISSN-L)
- 1477-0970
- OpenAlex
- W2111648933
- Cited by
- 145
- References
- 31
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 11 · 2023: 4 · 2022: 4 · 2021: 10 · 2020: 3 · 2019: 3 · 2018: 13 · 2017: 7 · 2016: 9 · 2015: 8 · 2014: 8 · 2013: 8 · 2012: 8
- FWCI
- 8.20
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Multiple Sclerosis Journal (publishedVersion)
- PubMed (publishedVersion)
- Florence Research (University of Florence) (submittedVersion)
- Institutional Research Information System University of Ferrara (University of Ferrara) (submittedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Multiple Sclerosis Research Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Protease and Inhibitor Mechanisms
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- multiple sclerosis, MMP-9, MMP-9/TIMP-1 ratio, TIMP-1, cerebrospinal fluid biomarkers, serum biomarkers, disease activity monitoring, relapsing-remitting multiple sclerosis, secondary progressive multiple sclerosis, primary progressive multiple sclerosis, MRI activity, immune dysregulation
- MeSH terms
- Adult, Enzyme Activation, Enzyme-Linked Immunosorbent Assay, Female, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Biomarkers, Tissue Inhibitor of Metalloproteinase-1, Multiple Sclerosis, Chronic Progressive, Multiple Sclerosis, Relapsing-Remitting, Matrix Metalloproteinase 9
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis. https://app.cochat.ai/papers/10.1191/135248506ms1274oa
- The paper
- Fainardi, E., Castellazzi, M., Bellini, T., Manfrinato, M. C., Baldi, E., Casetta, I., Paolino, E., Granieri, E., & Dallocchio, F. (2006). Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis. Multiple Sclerosis Journal. https://doi.org/10.1191/135248506ms1274oa
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.